Evotec announced an expanded restructuring that will close four sites and cut about one‑sixth of its workforce—roughly 800 positions—in a multiyear transformation aimed at rebalancing the German biotech and contract research organization. Company communications framed the move as part of a strategic refocus and cost optimization amid changing client demand and margins. Management said the changes would align capacity with current commercial realities while preserving core R&D and manufacturing strengths. The reorganization follows prior rounds of cost reductions and comes as Evotec seeks to streamline operations and remain competitive in discovery and CDMO markets. Employees, customers and partners will monitor execution risk and continuity of service. The cuts underscore ongoing consolidation pressures in the service provider sector even as demand for specialized biologics manufacturing remains strong.